Zeke Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Zeke Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,742	Closed	-$476K	–	563
2019 Q3	$476K	Buy	+1,742	New	+$639K	0.04%	367
2018 Q4	–	Sell	-572	Closed	-$523K	–	612
2018 Q3	$523K	Buy	572 +72	+14%	+$61.5K	0.04%	392
2018 Q2	$366K	Sell	500 -193	-28%	-$223K	0.03%	362
2018 Q1	$1.1M	Buy	693 +217	+46%	+$280K	0.1%	173
2017 Q4	$427K	Buy	+476	New	+$282K	0.04%	315

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Zeke Capital Advisors's NKTR Position: Q4 2019 in Review

Zeke Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 1,742 shares — an estimated $476K sold.

Zeke Capital Advisors first reported a position in NKTR in Q4 2017 and held it in 5 quarters. The position peaked at $1.1M in Q1 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Zeke Capital Advisors reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Zeke Capital Advisors sold 1,742 Nektar Therapeutics shares in Q4 2019, an estimated $476K.
Zeke Capital Advisors first reported a position in Nektar Therapeutics in Q4 2017 and held it in 5 quarters.
Zeke Capital Advisors's Nektar Therapeutics position peaked at $1.1M in Q1 2018.
281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Zeke Capital Advisors's 13F filing for Q4 2019, filed 17 Jan 2020.